Product Images Sacubitril And Valsartan
View Photos of Packaging, Labels & Appearance
- 1 - 606 15
- 1 - 607 15
- 1 - 608 13
- 1 - How Supplied
- figure-1 - sacubitril valsartan figure 1
- figure-2 - sacubitril valsartan figure 2
- sacubitril-valsartan-figure-3.jpg - sacubitril valsartan figure 3
- structure - sacubitril valsartan structure
- sacubitril-valsartanl-figure-4.jpg - sacubitril valsartanl figure 4
Product Label Images
The following 9 images provide visual information about the product associated with Sacubitril And Valsartan NDC 50268-607 by Avpak, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
1 - 606 15
This is not a valid text.*
1 - 607 15
This text provides information on a medication identified by its NDC code: 50268-607-15. The medication is Sacubitril and Valsartan Tablets containing 49 mg of sacubitril and 51 mg of valsartan. It consists of 50 tablets in a unit dose packaging of 5 x 10. The text mentions the dosage recommendation and storage instructions. The medication is available by prescription only.*
1 - 608 13
This is a description of Sacubitril and Valsartan Tablets with a strength of 97 mg/103 mg. The tablets are available in a unit dose pack of 30 tablets. The National Drug Code (NDC) for this product is 50268.608.13. Additionally, the text mentions dosage instructions and prescription details.*
1 - How Supplied
This text provides information about a tablet medication called SacubltiValsartan containing 24mg/26mg in purple, 49mg/51mg in light yellow, and 97mg/103mg in light pink. The tablets come in different packagings (10 tablets per card, 5 or 6 cards per carton) and are dispensed in unit dose packaging for institutional use only.*
figure-1 - sacubitril valsartan figure 1
This text provides the geometric mean ratio and 90% CI for various coadministered drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HeTZ, Metformin, Atorvastatin, and Sildenafil. It also mentions the change relative to reference.*
figure-2 - sacubitril valsartan figure 2
sacubitril-valsartan-figure-3.jpg - sacubitril valsartan figure 3
This text provides information on the time to first occurrence of cardiovascular death or heart failure hospitalizations in the PARADIGM-HF study. It includes data comparing the outcomes of patients treated with Sacubitril and Valsartan versus Enalapril. The text also presents data on the time to occurrence of cardiovascular death separately. The results show significant differences between the treatment groups in terms of these cardiovascular events. The text may be useful for healthcare professionals, researchers, or individuals interested in cardiovascular health and treatment outcomes in heart failure.*
structure - sacubitril valsartan structure
sacubitril-valsartanl-figure-4.jpg - sacubitril valsartanl figure 4
The text presents data on various subgroups including age, gender, weight, race, region, NYHA class, GFR, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP, hypertension, medication use, prior hospitalization, time since diagnosis, cause of heart failure, and presence of ICD. It also shows percentages of individuals within each category for treatment with Sacubitril and Valsartan as well as Enalapril, along with the Hazard Ratio. These statistics can be used to analyze the efficacy and impact of these medications on different demographic and health-related groups.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
